Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer

Kim A. Margolin, James H. Doroshow, Paul Frankel, Warren Chow, Lucille A. Leong, Dean Lim, Mark McNamara, Robert J. Morgan, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Yun Yen, Neil Kogut, Jeffrey Schriber, Joseph Alvarnas, Susan Stalter

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We evaluated the antitumor activity of tandem cycles of high-dose chemotherapy with autologous peripheral stem cell transplantation (aPSCT) in relapsed germ cell tumors by using high-dose paclitaxel, carboplatin, etoposide, and ifosfamide. Thirty-three patients were entered, and 31 underwent protocol therapy. Paclitaxel 350 mg/m2 (5 patients) or 425 mg/m2 (26 patients) by 24-hour continuous intravenous infusion was followed by 3 daily doses of carboplatin and either etoposide (cycle 1) or ifosfamide/mesna (cycle 2). The carboplatin dose had a calculated area under the curve of 7 mg-min/mL, and the daily dose of etoposide was 20 mg/kg (cycle 1). Ifosfamide 3 g/m2/d for 3 days (with mesna uroprotection) was substituted for etoposide in cycle 2. Each cycle was supported by granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Thirty-one patients were evaluable for response, toxicity, and long-term disease control. Two patients did not undergo aPSCT because of rapid disease progression. Nineteen patients received both cycles of aPSCT, 8 progressed after cycle 1, 3 refused the second cycle, and 1 died of fungal infection during cycle 1. Twelve patients remain relapse free at a median of 67 months from the initiation of therapy. Whereas the International Germ Cell Cancer Collaborative Group category at the time of initial diagnosis did not seem to predict outcome, the patient's probability of achieving durable remission was significantly associated with the Beyer prognostic score at the time of protocol entry. Regimens containing the most active agents in relapsed nonseminomatous germ cell tumors, including high-dose paclitaxel, are well tolerated and have promising activity even in patients with poor-risk features who do not achieve durable remissions with standard therapy. The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT.

Original languageEnglish
Pages (from-to)903-911
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 1 2005
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Paclitaxel
Stem Cells
Drug Therapy
Peripheral Blood Stem Cell Transplantation
Etoposide
Ifosfamide
Carboplatin
Mesna
Activity Cycles
Mycoses
Granulocyte Colony-Stimulating Factor
Intravenous Infusions
Area Under Curve
Disease Progression
Therapeutics
Recurrence

Keywords

  • Autologous peripheral stem cell support
  • Germ cell tumors
  • High-dose chemotherapy
  • Paclitaxel

ASJC Scopus subject areas

  • Transplantation

Cite this

Margolin, K. A., Doroshow, J. H., Frankel, P., Chow, W., Leong, L. A., Lim, D., ... Stalter, S. (2005). Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. Biology of Blood and Marrow Transplantation, 11(11), 903-911. https://doi.org/10.1016/j.bbmt.2005.07.010

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. / Margolin, Kim A.; Doroshow, James H.; Frankel, Paul; Chow, Warren; Leong, Lucille A.; Lim, Dean; McNamara, Mark; Morgan, Robert J.; Shibata, Stephen; Somlo, George; Twardowski, Przemyslaw; Yen, Yun; Kogut, Neil; Schriber, Jeffrey; Alvarnas, Joseph; Stalter, Susan.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 11, 01.11.2005, p. 903-911.

Research output: Contribution to journalArticle

Margolin, KA, Doroshow, JH, Frankel, P, Chow, W, Leong, LA, Lim, D, McNamara, M, Morgan, RJ, Shibata, S, Somlo, G, Twardowski, P, Yen, Y, Kogut, N, Schriber, J, Alvarnas, J & Stalter, S 2005, 'Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer', Biology of Blood and Marrow Transplantation, vol. 11, no. 11, pp. 903-911. https://doi.org/10.1016/j.bbmt.2005.07.010
Margolin, Kim A. ; Doroshow, James H. ; Frankel, Paul ; Chow, Warren ; Leong, Lucille A. ; Lim, Dean ; McNamara, Mark ; Morgan, Robert J. ; Shibata, Stephen ; Somlo, George ; Twardowski, Przemyslaw ; Yen, Yun ; Kogut, Neil ; Schriber, Jeffrey ; Alvarnas, Joseph ; Stalter, Susan. / Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. In: Biology of Blood and Marrow Transplantation. 2005 ; Vol. 11, No. 11. pp. 903-911.
@article{88030aca59c347deb63b31c8dcf7df18,
title = "Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer",
abstract = "We evaluated the antitumor activity of tandem cycles of high-dose chemotherapy with autologous peripheral stem cell transplantation (aPSCT) in relapsed germ cell tumors by using high-dose paclitaxel, carboplatin, etoposide, and ifosfamide. Thirty-three patients were entered, and 31 underwent protocol therapy. Paclitaxel 350 mg/m2 (5 patients) or 425 mg/m2 (26 patients) by 24-hour continuous intravenous infusion was followed by 3 daily doses of carboplatin and either etoposide (cycle 1) or ifosfamide/mesna (cycle 2). The carboplatin dose had a calculated area under the curve of 7 mg-min/mL, and the daily dose of etoposide was 20 mg/kg (cycle 1). Ifosfamide 3 g/m2/d for 3 days (with mesna uroprotection) was substituted for etoposide in cycle 2. Each cycle was supported by granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Thirty-one patients were evaluable for response, toxicity, and long-term disease control. Two patients did not undergo aPSCT because of rapid disease progression. Nineteen patients received both cycles of aPSCT, 8 progressed after cycle 1, 3 refused the second cycle, and 1 died of fungal infection during cycle 1. Twelve patients remain relapse free at a median of 67 months from the initiation of therapy. Whereas the International Germ Cell Cancer Collaborative Group category at the time of initial diagnosis did not seem to predict outcome, the patient's probability of achieving durable remission was significantly associated with the Beyer prognostic score at the time of protocol entry. Regimens containing the most active agents in relapsed nonseminomatous germ cell tumors, including high-dose paclitaxel, are well tolerated and have promising activity even in patients with poor-risk features who do not achieve durable remissions with standard therapy. The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT.",
keywords = "Autologous peripheral stem cell support, Germ cell tumors, High-dose chemotherapy, Paclitaxel",
author = "Margolin, {Kim A.} and Doroshow, {James H.} and Paul Frankel and Warren Chow and Leong, {Lucille A.} and Dean Lim and Mark McNamara and Morgan, {Robert J.} and Stephen Shibata and George Somlo and Przemyslaw Twardowski and Yun Yen and Neil Kogut and Jeffrey Schriber and Joseph Alvarnas and Susan Stalter",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2005.07.010",
language = "English",
volume = "11",
pages = "903--911",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer

AU - Margolin, Kim A.

AU - Doroshow, James H.

AU - Frankel, Paul

AU - Chow, Warren

AU - Leong, Lucille A.

AU - Lim, Dean

AU - McNamara, Mark

AU - Morgan, Robert J.

AU - Shibata, Stephen

AU - Somlo, George

AU - Twardowski, Przemyslaw

AU - Yen, Yun

AU - Kogut, Neil

AU - Schriber, Jeffrey

AU - Alvarnas, Joseph

AU - Stalter, Susan

PY - 2005/11/1

Y1 - 2005/11/1

N2 - We evaluated the antitumor activity of tandem cycles of high-dose chemotherapy with autologous peripheral stem cell transplantation (aPSCT) in relapsed germ cell tumors by using high-dose paclitaxel, carboplatin, etoposide, and ifosfamide. Thirty-three patients were entered, and 31 underwent protocol therapy. Paclitaxel 350 mg/m2 (5 patients) or 425 mg/m2 (26 patients) by 24-hour continuous intravenous infusion was followed by 3 daily doses of carboplatin and either etoposide (cycle 1) or ifosfamide/mesna (cycle 2). The carboplatin dose had a calculated area under the curve of 7 mg-min/mL, and the daily dose of etoposide was 20 mg/kg (cycle 1). Ifosfamide 3 g/m2/d for 3 days (with mesna uroprotection) was substituted for etoposide in cycle 2. Each cycle was supported by granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Thirty-one patients were evaluable for response, toxicity, and long-term disease control. Two patients did not undergo aPSCT because of rapid disease progression. Nineteen patients received both cycles of aPSCT, 8 progressed after cycle 1, 3 refused the second cycle, and 1 died of fungal infection during cycle 1. Twelve patients remain relapse free at a median of 67 months from the initiation of therapy. Whereas the International Germ Cell Cancer Collaborative Group category at the time of initial diagnosis did not seem to predict outcome, the patient's probability of achieving durable remission was significantly associated with the Beyer prognostic score at the time of protocol entry. Regimens containing the most active agents in relapsed nonseminomatous germ cell tumors, including high-dose paclitaxel, are well tolerated and have promising activity even in patients with poor-risk features who do not achieve durable remissions with standard therapy. The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT.

AB - We evaluated the antitumor activity of tandem cycles of high-dose chemotherapy with autologous peripheral stem cell transplantation (aPSCT) in relapsed germ cell tumors by using high-dose paclitaxel, carboplatin, etoposide, and ifosfamide. Thirty-three patients were entered, and 31 underwent protocol therapy. Paclitaxel 350 mg/m2 (5 patients) or 425 mg/m2 (26 patients) by 24-hour continuous intravenous infusion was followed by 3 daily doses of carboplatin and either etoposide (cycle 1) or ifosfamide/mesna (cycle 2). The carboplatin dose had a calculated area under the curve of 7 mg-min/mL, and the daily dose of etoposide was 20 mg/kg (cycle 1). Ifosfamide 3 g/m2/d for 3 days (with mesna uroprotection) was substituted for etoposide in cycle 2. Each cycle was supported by granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Thirty-one patients were evaluable for response, toxicity, and long-term disease control. Two patients did not undergo aPSCT because of rapid disease progression. Nineteen patients received both cycles of aPSCT, 8 progressed after cycle 1, 3 refused the second cycle, and 1 died of fungal infection during cycle 1. Twelve patients remain relapse free at a median of 67 months from the initiation of therapy. Whereas the International Germ Cell Cancer Collaborative Group category at the time of initial diagnosis did not seem to predict outcome, the patient's probability of achieving durable remission was significantly associated with the Beyer prognostic score at the time of protocol entry. Regimens containing the most active agents in relapsed nonseminomatous germ cell tumors, including high-dose paclitaxel, are well tolerated and have promising activity even in patients with poor-risk features who do not achieve durable remissions with standard therapy. The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT.

KW - Autologous peripheral stem cell support

KW - Germ cell tumors

KW - High-dose chemotherapy

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=27844528490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844528490&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.07.010

DO - 10.1016/j.bbmt.2005.07.010

M3 - Article

C2 - 16275593

AN - SCOPUS:27844528490

VL - 11

SP - 903

EP - 911

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -